BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gkiougki E, Mitsiakos G, Chatziioannidis E, Papadakis E, Nikolaidis N. Predicting Response to rFVIIa in Neonates With Intractable Bleeding or Severe Coagulation Disturbances. Journal of Pediatric Hematology/Oncology 2013;35:221-6. [DOI: 10.1097/mph.0b013e318286d27e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Davenport P, Sola-Visner M. Hemostatic Challenges in Neonates. Front Pediatr 2021;9:627715. [PMID: 33738269 DOI: 10.3389/fped.2021.627715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cosar H, Isik H, Cakır SC, Yar N, Goksen B, Tokbay H, Kertmen H, Erdoğan N, Durak I. Recombinant Activated Factor VIIa (rFVIIa) Treatment in Very-Low-Birth-Weight (VLBW) Premature Infants with Acute Pulmonary Hemorrhage: A Single-Center, Retrospective Study. Paediatr Drugs 2017;19:53-8. [PMID: 27826851 DOI: 10.1007/s40272-016-0203-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Bafaqih H, Chehab M, Almohaimeed S, Thabet F, Alhejaily A, AlShahrani M, Zolaly MA, Abdelmoneim AA, Abd ES. Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage. Ann Saudi Med 2015;35:231-9. [PMID: 26409798 DOI: 10.5144/0256-4947.2015.231] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]